Since Pear Therapeutics, one of the earliest digital therapeutic companies, declared bankruptcy in April, there’s been discussion surrounding the state of investments in digital therapeutics, challenges that exist around standards of care, barriers to adoption and how to achieve success in the sector.
Andy Molnar, CEO of the Digital Therapeutics Alliance, a nonprofit organization that provides thought leadership and education to advance digital therapeutic adoption, sat down with MobiHealthNews to provide his insight into the digital therapeutic market and how Pear’s bankruptcy has affected the industry.
“We’re still keeping everything moving forward as smart as we can be today,” he said. “I mean digital therapeutics, prescription digital therapeutics and digital health in general is obviously not going away. It’s here to stay, and we’re here to help guide it. And five years ago when we started, we just weren’t as smart as we are now. Maybe it’s just a nice reset, you know? Many people say, okay, how much money does it really take? How much do we really need? Where do you put your resources?” Read more.
